key: cord-0839890-wgx1kej7
authors: Rashad, Alaa; Nafady, Asmaa; Hassan, Mohammed H.; Mansour, Haggagy; Taya, Usama; Bazeed, Shamardan Ezzeldin S.; Aref, Zaki F.; Sayed, Mennatallah Ali Abdelrhman; Nafady-Hego, Hanaa; Abdelmaksoud, Aida A.
title: Therapeutic efficacy of macrolides in management of patients with mild COVID-19
date: 2021-08-11
journal: Sci Rep
DOI: 10.1038/s41598-021-95900-z
sha: 2dea4938f31a80651ad5a92b5a7eb8ab177da793
doc_id: 839890
cord_uid: wgx1kej7

Evidence on the efficacy of adding macrolides (azithromycin or clarithromycin) to the treatment regimen for COVID-19 is limited. We testify whether adding azithromycin or clarithromycin to a standard of care regimen was superior to standard of supportive care alone in patients with mild COVID-19.This randomized trial included three groups of patients with COVID-19. The azithromycin group included, 107 patients who received azithromycin 500 mg/24 h for 7 days, the clarithromycin group included 99 patients who received clarithromycin 500 /12 h for 7 days, and the control group included 99 patients who received standard care only. All three groups received only symptomatic treatment for control of fever and cough .Clinical and biochemical evaluations of the study participants including assessment of the symptoms duration, real-time reverse transcription-polymerase chain reaction (rRT-PCR), C-reactive protein (CRP), serum ferritin, D-dimer, complete blood count (CBC), in addition to non-contrast chest computed tomography (CT), were performed. The overall results revealed significant early improvement of symptoms (fever, dyspnea and cough) in patients treated with either azithromycin or clarithromycin compared to control group, also there was significant early conversion of SARS-CoV-2 PCR to negative in patients treated with either azithromycin or clarithromycin compared to control group (p < 0.05 for all).There was no significant difference in time to improvement of fever, cough, dyspnea, anosmia, gastrointestinal tract "GIT" symptoms and time to PCR negative conversion between patients treated with azithromycin compared to patients treated with clarithromycin (p > 0.05 for all). Follow up chest CT done after 2 weeks of start of treatment showed significant improvement in patients treated with either azithromycin or clarithromycin compared to control group (p < 0.05 for all).Adding Clarithromycin or azithromycin to the therapeutic protocols for COVID-19 could be beneficial for early control of fever and early PCR negative conversion in Mild COVID-19. Trial registration: (NCT04622891) www.ClinicalTrials.gov retrospectively registered (November 10, 2020).

| (2021) 11:16361 | https://doi.org/10.1038/s41598-021-95900-z www.nature.com/scientificreports/ trial as tocilizumab and sarilumab can attenuate COVID-19 and associated cytokine storm by interfering with interleukin- 6 7,8 , also the mesenchymal stem cell therapy described earlier 9 . The therapeutic use of convalescent plasma therapy in critically ill patients with COVID-19 has recently emerged. Isolating the SARS-CoV-2 diseaseassociated antibodies from the population of recovered patients would be considerably more advantageous if done in accordance with the disease's regional distribution. For the treatment of SARS-CoV-2 patients, raised antibodies should be manufactured on a large scale. These antibodies could provide an immediate strategy for SARS-CoV-2 treatment while the alternative, more time-consuming process of developing vaccines and new medicines continues 10 .

Azithromycin is a widely available drug that might decrease viral load when added to hydroxychloroquine in patients with non-severe COVID-19 11, 12 . Furthermore, preclinical studies have reported immunomodulatory effects of azithromycin and other macrolides, which could control the intense inflammatory responses that might cause progression to organ failure [4] [5] [6] [7] .

Macrolides are bacteriostatic antibiotics, which are widely used in clinical practice against respiratory tract pathogens as gram-positive and atypical bacterial have been shown to have immunomodulatory and anti-inflammatory effects [13] [14] [15] . Macrolides have a glycosylic bond connects amino sugar and/or neutral sugar moieties to form a macro-lactone ring of variable size (12-22 carbon atoms) . The only 15-membered ring is azithromycin (AZI), a macrolide derivative known as an azalide. (CLA) is 14-membered macrolide, has largely replaced erythromycin (ERY) in clinical practice 16, 17 . The anti-inflammatory potential of macrolides to reduce the production of matrix metalloproteinases (MMPs), tumor necrosis factor-alpha (TNF−), interleukin (IL)-6, and IL-8 has been reported in critical cases 18 .

The antibiotic azithromycin suppressed the increase in mucin and TNF-α levels in respiratory epithelial cells from several human patients. It also helps to repair damaged tissues caused by inflammation because of its connection to the T-helper (TH) phenotype. Clarithromycin could regulate viral respiratory tract inflammatory infections by lowering sialic acid α 2,6-galactose sialyloligosaccharides (SA2,6Gal), partially inhibiting NF-κB, and raising endosome pH in respiratory epithelial cells [19] [20] [21] . The anti inflammatory mechanism of clarithromycin through inhibiting the activation of NF-kB in cell nuclei and transcription reduction make it a good candidate drug in COVID-19 setting as most of the disease pathology is due to inflammation 22 . Together with the suppressing effect of clarithromycin on SAα 2,6Gal, a receptor for human influenza located on human tracheae surface mucosa, and prevents viral invasion, will lead to protein synthesis inhibition, translocation of aminoacyl transfer-RNA, and preventing peptide chain elongation. The same scenario can happen in SARS-Cov-2 viral infection 23 .

To date, evidence on the efficacy and safety of adding azithromycin or clarithromycin to the treatment regimen for mild/ moderate COVID-19 is limited by low-quality studies 10, 11, 14 . The main objective of the current research is to address the effectiveness of these drugs in improving the clinical status and fasten PCR negative conversion in patients with mild COVID-19.

Study design and participants. The current study is a clinical trial conducted at Qena Governorate, Egypt, during the period from May 2020, to September 2020. An institutional ethical committee approval, Faculty of Medicine, South Valley University, Qena, Egypt, was taken, Ethical approval code: SVU202(SVU-CHT019-420860). A written informed consent was taken from all the patients participate in this study and the procedures were in accordance to Helsinki guidelines for human research.

Our study included 305 confirmed cases of mild COVID-19 according to WHO classification of clinical cases and all of them received the standard care regimen. They have active COVID-19, Oxygen saturation > 90% on room air and imaging shows less than 25% infiltrates on CT chest. They were randomly assigned to one of three study groups. The azithromycin group included, 107 patients who received oral azithromycin 500 mg/24 h for 7 days, the clarithromycin group included 99 patients who received oral clarithromycin 500 /12 h for 7 days, and the control group included 99 patients who received standard care only. All three groups received standard care regimen to control fever (paracetamol) and cough. The three included groups of patients were matched regarding to age, sex, and body mass index (BMI), they were non-smokers and not have any co-morbidities. Patients were followed in intermediate care facility for quarantine of mild COVID-19 cases. The study flow chart done in intermediate care facility for quarantine of mild COVID-19 cases was presented in (Fig. 1) . Not all included patients at the start of the study were reported in this data because they did not follow up with CT or consent withdraws either because they were recovered or due to limited funding sources.

All study participants underwent full clinical evaluation including duration of fever, cough, dyspnea, anosmia or gastrointestinal tract "GIT" symptoms, daily evaluation of symptoms was done, fever chart was plotted 3 times daily measurement, patient was considered a febrile if body temprature < 37.2 C for two consecutive days. During the study period, an electroencephalogram (ECG) was performed on a regular basis to detect any potential cardiac arrhythmias caused by macrolides therapy, especially prolonged QT interval.

A. Prior to therapy, 6 mls of venous blood were collected from each patient and divided into three parts: (2 mls were evacuated into EDTA tubes for CBCs; 2 mls were evacuated into serum gel separator tubes and allowed to clotted at 37 0C for 30 min until centrifugation at 3500 rpm for 10 min, and the separated sera were used for C-reactive protein (CRP) and ferritin assays, while the remaining 2 mls were calibrated to be evacuated into citrate tubes, and the separated citrated plasma was used for D-dimmer assays after centrifugation) as follows: 

Baseline demographic, clinical, laboratory and imaging data of the study groups. The current study included 305 confirmed cases of mild COVID-19 who were allocated into three groups. The azithromycin group included, 107 patients, mean age 45.8 ± 18 years, 73 male and 34 female, the clarithromycin group included 99 patients mean age 46.1 ± 19 years, 68 males and 31 female, the control group included 99 patients, with mean age 41.1 ± 18 years, 73 male and 28 female with non-significant differences between the study groups regarding to the age and sex, indicating matching, p > 0.05 for all ( Table 1) . As regards the baseline clinical and laboratory data, there were no significant differences in the frequency percentage of fever, cough, dyspnea and anosmia, or the mean ± SD of the baseline CRP, serum ferritin, nutrophil/ lymphocyte ratio and D-dimer , or the extent of CT chest infiltrates between azithromycin, clarithromycin or control groups, p > 0.05 for all (Table 1) .

There was significant shorter duration of fever (days), in patients treated with either azithromycin (5.2 ± 2.3) or clarithromycin (4.9 ± 1.5) compared to control group (12.9 ± 2.2), P < 0.000. Duration of cough also showed significant fewer days for improvment in patients treated with either azithromycin (5.4 ± 2.7) or clarithromycin (5.1 ± 2) compared to control group (12.9 ± 2.2) P < 0.0001, in addition, dyspnea duration (days) showed significant early improvement in patients treated with either azithromycin (4.6 ± 3.3) or clarithromycin (4.7 ± 2.9) compared to control group (9.3 ± 2.7), P < 0.0001 (Table 2 ). There was significant early conversion (days) of SARS-CoV-2 PCR to negative in patients treated with either azithromycin (8.7 ± 2.8) or clarithromycin (8.3 ± 2.6) compared to control group (13.2 ± 4.2), P < 0.0001 (Table 2) .

There was no significant difference in time to improvement of fever (P = 0.351), cough (P = 0.481), dyspnea (P = 0.726), and time to PCR negative conversion (P = 0.351) between patients treated with azithromycin compared to patients treated with clarithromycin ( Table 2) .

Follow up chest CT chest done 2 weeks after the start of treatment showed significant improvement in patients treated with either azithromycin 70 (65%) or clarithromycin 76 (77%) compared to control group 53 (54%) P < 0.0001, ( Table 2 ).

In terms of the survival analysis, our study protocol stated that the follow-up period would be 7 days only, and none of the patients would die during that time. Furthermore, none of the patients who were included in the study complained of arrhythmias or chest pain. 

COVID-19 care presented significant problems to physicians and specialists, in part due to the disease's novelty and the severe symptoms it causes. Vaccination, despite its recent introduction, is still only used in a limited number of situations. Identifying safe and effective therapeutic options for the treatment of such a highly contagious disease is crucial in this scenario 26 . Antiviral therapies or neutralizing monoclonal antibodies should be used to treat the causal virus as soon as possible; however, treating the underlying inflammatory disease may not be beneficial. The antiviral effect of macrolids was originally discovered in individuals with widespread pan bronchitis who were given a modest dose of erythromycin and saw a reduction in inflammation in the upper and lower respiratory tract 27 . Clarithromycin's efficacy against viral infections such as rhinovirus (RV), respiratory syncytial virus (RSV), and influenza virus has been studied previously [28] [29] [30] [31] .

In this trial, two groups of patients were randomly assigned to receive either azithromycin or clarithromycin in addition to standard care, and were compared to a third group that only got standard care. The average mean of age was comparable among the 3 study groups (azithromycin was 45.8 years, clarithromycin was 46.1 years, and control group was 41.1 years respectively, P > 0.05). Before starting the therapy regimen, the clinical and laboratory investigations of the patients do not differ. Fever, dyspnea, and cough improved significantly, and SARS-CoV-2 PCR was converted to negative in both azithromycin and clarithromycin groups earlier than in the control group. The benefit-risk profile of macrolides in COVID-19 patients is currently being discovered. According to clinicaltrials.gov, there are now 20 ongoing research trials using azithromycin, either alone or in combination with other drugs, in COVID-19 32 . Azithromycin pretreatment of COVID-19 patients can minimize LPS-induced lung bioluminescence and airway cell infiltration, lower the amount of proinflammatory cytokines in bronchoalveolar lavage, and inhibit NF-kβ nuclear translocation, according to a study by Stellari et al. 33 . In the other hand, a total of 1438 hospitalized patients with COVID-19 were included in one trial. 735 (51.1%) were given hydroxychloroquine with azithromycin, 271 (18.8%) were given hydroxychloroquine alone, 211 (14.7%) were given azithromycin alone, and 221 (15.4%) were given other medications. In-hospital mortality did not differ significantly when statistical analyses were adjusted 34 . It's important to note that their patients weren't in the same circumstances as ours, who were mild cases for which azithromycin or clarithromycin would still have a chance to suppress the immune response and lower cytokine expression before severe inflammation and problems developed. They also failed to account for the time required for PCR negative conversion. In agreement, Gautret et al. reported that in six patients, combining azithromycin with hydroxychloroquine resulted in statistically higher viral clearance (6/6, 100%) compared to hydroxychloroquine monotherapy (8/14, 57%) 35 . In contrast, a report that comprised randomized trials comparing macrolides-as monotherapy or in combination with other medications-to placebo or no treatment in patients with COVID-19 indicated that macrolides had no benefit in the management of COVID-19 patients compared to standard of care. All of the evidence was inconclusive, thus a larger trial was advised 36 . Cavalcanti et al. found that hydroxychloroquine, either alone or in combination with azithromycin, did not improve clinical status at 15 days as compared to standard therapy in patients hospitalized with mild-to-moderate COVID-19 37 .

The use of a chest CT scan in the early diagnosis of COVID-19 patients is critical 35 . As time passes as the disease progresses, the radiological results tend to become more confluent and bilateral. Dense consolidations with ground glass opacities (GGOs) are an example of this 36 . There was a substantial reduction in lung infiltrates in patients treated with azithromycin or clarithromycin compared to the control group when it came to the effect of macrolides therapy on radiological findings of the included patients. In confirmation of azithromycin's importance in treating COVID-19, a survey of 6200 physicians in 30 countries found that azithromycin was the second most regularly recommended antibiotic for COVID-19 treatment 37 . Based on our results we concluded that, azithromycin or clarithromycin when used in mild COVID-19 cases are safe and effective adjunctive therapy for alleviating the early symptoms, viral shedding that can reduce viral transmission. 

The current study provides evidence for the use of macrolids (clarithromycin or azithromycin) in mild COVID-19 treatment protocols, which could be effective for early fever management and PCR negative conversion. More research into macrolids' safety and efficacy, as well as their use in conjunction with other regularly used therapy modalities, is needed.

The study's main limitations were the small sample size, single-center analysis, and absence of long-term comparative follow-up of the included patients to determine any late complications, protection duration, and the probability of re-infection after complete COVID-19 cure.

Received: 8 February 2021; Accepted: 26 July 2021

Outbreak of novel coronavirus (SARS-Cov-2): First evidences from International Scientific Literature and Pending Questions

Designing of cytotoxic and helper T cell epitope map provides insights into the highly contagious nature of the pandemic novel coronavirus SARS-CoV-2

Indicators of critical illness and predictors of mortality in COVID-19 patients

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Compounds with therapeutic potential against novel respiratory 2019 coronavirus

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Effective treatment of severe COVID-19 patients with tocilizumab

Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically Ill COVID-19 patients: The case for compassionate use

Current perspectives of convalescent plasma therapy in COVID-19

Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?

Mechanisms of action and clinical application of macrolides as immunomodulatory medications

Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases

Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond

Azithromycin: the first azalide antibiotic

Azithromycin modulates immune response of human monocyte-derived dendritic cells and CD4+ T cells

Azithromycin alters macrophage phenotype

Macrolides attenuate phorbol ester-induced tumor necrosis factor-α and mucin production from human airway epithelial cells

Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells

Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells

Azithromycin and clarithromycin: overview and comparison with erythromycin

Olfactory disturbances as presenting manifestation among Egyptian patients with COVID-19: Possible role of zinc

Characteristics, outcomes and indicators of severity for COVID-19 among sample of ESNA Quarantine Hospital's Patients, Egypt: A retrospective study

Combination of hydroxychloroquine plus azithromycin as potential treatment for COVID-19 patients: safety profile, drug interactions, and management of toxicity

Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis

Effects of macrolides on airway microbiome and cytokine of children with bronchiolitis: A systematic review and meta-analysis of randomized controlled trials

Efficacy of antibiotics against influenza-like illness in an influenza epidemic

Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells

Clarithromycin inhibits progeny virus production from human influenza virusinfected host cells

Azithromycin in COVID-19 patients: Pharmacological mechanism, clinical evidence and prescribing guidelines

Azithromycin inhibits nuclear factor-κB activation during lung inflammation: an in vivo imaging study

Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Macrolides for the treatment of COVID-19: a living, systematic review

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Chest CT imaging features of typical covert COVID-19 cases

CT chest findings in coronavirus disease-19 (COVID-19)

Largest statistically significant study by 6,200 multi-country physicians on COVID-19 uncovers treatment patterns and puts pandemic in context

All authors contributed equally to this work and approved the final version of the manuscript.

This research was partially funded by South Valley University, faculty of Medicine, Qena83523, Egypt.

The authors declare no competing interests.

Correspondence and requests for materials should be addressed to M.H.H.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.